The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Early May was mentioned in the FDA update RNS of 4th March
Quote:
"Some of the technical information requested necessitates some targeted additional analytical studies. However, these additional analytical studies do not require patient samples and ANGLE anticipates that the necessary studies, which are already at an advanced planning stage, can be completed and the response submitted by early May. "
SLF72 You might find the Q&A section of this presentation interesting, from around 19mins.
https://www.youtube.com/watch?v=X-ux25RcGw4
Basically Andrew talks about Parsotix being used on people who are already a high risk ,such as a woman with a diagnosed pelvic mass. Parsortix can then determine if the mass is cancer or not.
Presumably it would be the same for breast cancer.
Total shares in issue is 591,609,368 according the latest RNS.
On the Nuformix website main page the "Company overview" has shares in issue as 469.47million and the wrong market cap.
They need to tidy up things like this.
Just an idea, but we had the 18 million sell(?) then the pair of 9 and a bit million sells yesturday. That adds up to close to Dan's holding. Is it possible he has dumped his stock?
Obviously this shows the importance of issuing TR1s on time so people don't come up with wild theories.
Either way, the fact that all the stock is being bought shows there is still an appetite for NFX dispite all that has happened.
To put that in perspective, OPRH was valued at less than £20 million before the hVivo acquisition.
Interesting that you mention ORPH BOJO. I've been in ORPH since the beginning and it was ORPH that accidently introduced me to AGL.
I was waiting for ORPH to present on Proactive last August and AGL were on first. I had never heard of AGL but Andrew Newland presented very well and I was intrigued. I watched the presentation again, then every other presentation and interview I could find. It seemed like years of work were reaching an inflection point so I bought in. I was also very lucky to be able to take advantage of the Jupiter sell off.
Very happy to see where this goes in the next few years.
So Crystal Amber reduce back to the level they were at in October last year.
Interestingly they increased their stake in HUR by about the same amount on the same day.
That seems like a brave move considering the state of HUR.
Good that it explains the large sell that Paul Hill mentioned was responsible for the price drop last week.
I wonder if some PIs misunderstood something Tony said in a recent interview when he said commisioning would finish and sales in the "June quarter". Maybe some took that to mean there is a delay till June itself, rather than April which is obviously in the June quarter.
The interview was on the 23rd and he said full load commisioning was in a few weeks time, so is probably happening around now. Presumably the first shipment of product should follow soon after.
The 2020 figures were largely known from the Jan trading update. The main story here for me is that Q1 was good despite the UK being in lockdown for the entire period. As the economy opens up, the numbers will only get better.
I agree that he is underplaying it. CF has often said that the hVivo clinc could do around £45 million a year revenue, but that was with £3-5 million contracts. If he intends to sign £7.5-10 million contracts then it will do closer to £100 million. If they can keep the 2nd facility full and continue the covid work then the core business will be certainly get close to that $1 billion valuation based just on revenue.
Like a few others on this board I found EQLS last year following Paul Hills favourable analysis. Very happy with progress so far.
What do people think is the long term future though? From interviews I've seen of people in this sector it seems that you aquire or get acquired. Crystal Amber make the point in their analysis that EQLS would be an "attractive takeover candidate".
Is it therefore inevitable that EQLS gets bought in the next few years?
Or do they continue to aquire and grow into a much larger business.
Could they pay a dividend?
Certainly Explains the rise first thing. Supprised it dropped back so much in the afternoon. Wonder if the buyer will be active tomorrow as well.
I am assuming that any rise would be sold into. I believe there are potentially 3 large sellers still out there.
Soup's research was outstanding. He may be the most knowledable and well researched poster I've seen on any company.
Hopefully some money does come though from Ebers but the timescale is my concern there. Even if Ebers started selling product tomorrow, how long would it be before NFX starts receiving payments.
Very interesting post yuyus.
You had a similar year to me. I was also disappointed by Hurricane but took some profit from Avacta and Novacyt. I also found AGL at the end of the year and got a cheap entry thanks to Jupiter.
Like you I'm very excited by AGL.
I think the difference is I lost my NFX FOMO in the middle of the year. I sold most of my NFX holding at 3p and put it into ORPH at 11p which was already my biggest holding. It helped regain NFX losses.
My reasoning to get over FOMO was that the price had dropped so far that even if the magical RNS did land and the price opened 100% up, it would still be cheap to get in. People were happy paying 8p and 10p after the NXP001 results,
Before I buy back in here I would like to see a deal land with enough cash to prevent another placing and also see the BOD buy some shares.
You can see an interview with an ii, Gervais Williams of Premier Miton below. According to Morning Star, they own under 1%.
They've taken some profits but are still holding and think momentum is strong into next year.
Talks about ORPH from 12:40
https://www.youtube.com/watch?v=yEx6N-j6p5k
That was an interesting comment. It backs up the post on here earlier in the week that showed the II holdings and that they didn't appear to be selling.
Question. Some of the IIs are the ones that Cathal brought in when he founded Orph. Are they locked in for 3 years like Cathal and the other founding directors?
Chinese New Year wasn't it?
Once Dan had gone, were people expecting it to take this long to appoint a new CEO? 4.5 months and counting!
Are they even looking for one?
I've always understood the 24 bed clinic would generate between £45 and £50m. Cathal has been fairly consistant on that.
The lab should generate an additional £5 to £10m as stated in the presentation. Then there is the Venn side of the business and the data base.
There is also £40m of covid challenge studies booked in the Royal Free.
£43m sounds like a very out of date number.
A vaccine on the horizon should be good news for NFX. They've used Covid as an excuse for the slow progress this year.
Once Covid start to disappear they will either need to make some progress or find another excuse.